Company intelligence / Profile preview
Naia
Cayman Islandsnaiapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NB1001, a long‑acting GLP‑1 agonist using XTEN technology, demonstrated efficacy and up to a month-long half-life in a clinical study for SBS and received orphan drug designation. The company’s pipeline includes additional GLP-based therapies and small molecules targeting rare GI and metabolic diseases
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Peptide (GLP receptor agonists)Small molecule (for metabolic disease program NC101)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Amunix Operating Inc.Pharco PharmaceuticalsCedars-Sinai Medical Center
Beyond the preview
Go deeper on Naia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Naia.